Company intelligence / Profile preview
Lucy Therapeutics
Waltham, Massachusetts, United Stateslucytherapeutics.com ↗
- Ownership
- Public · LSDI
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Lucy Therapeutics has validated neuroprotective effects of its small molecule candidates in multiple animal models for CNS diseases. The company has identified development candidates for both Rett syndrome and Parkinson's programs. IND filings are planned for all three lead programs in Alzheimer’s, Parkinson’s, and Rett syndrome in or after 2025; no clinical results have been reported yet as the company remains preclinical.
- Therapeutic areas
- Neurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Lucy Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lucy Therapeutics.